The experience of successful treatment of
ETV6-NTRK3
-positive infant glioblastoma with entrectinib
Neurooncol Adv
.
2021 Feb 3;3(1):vdab022.
doi: 10.1093/noajnl/vdab022.
eCollection 2021 Jan-Dec.
Authors
Ludmila Papusha
1
,
Margarita Zaytseva
1
,
Alexander Druy
1
,
Andge Valiakhmetova
1
,
Ludmila Yasko
1
,
Ekaterina Salnikova
1
,
Anastasia Shekhtman
1
,
Alexander Karachunsky
1
,
Alexey Maschan
1
,
Eugene I Hwang
2
3
,
Galina Novichkova
1
,
Roger J Packer
2
3
Affiliations
1
D. Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
2
Center for Neuroscience and Behavioral Medicine, Brain Tumor Institute, Washington, District of Columbia, USA.
3
Children's National Health System, Washington, District of Columbia, USA.
PMID:
33738452
PMCID:
PMC7954097
DOI:
10.1093/noajnl/vdab022
No abstract available